padsevonil + erythromycin

Padsevonil + erythromycin refers to the coadministration of two distinct drugs: padsevonil, a small molecule antiseizure medication developed for drug-resistant epilepsy, and erythromycin, a macrolide antibiotic often used as a CYP3A4 inhibitor in pharmacokinetic and drug-drug interaction studies. Padsevonil acts as an agonist at synaptic vesicle 2 proteins (including SV2A, SV2B, and SV2C) and at the GABA-A receptor, contributing to its antiepileptic activity. Erythromycin, in this context, is primarily used for its potent inhibition of cytochrome P450 3A4 (CYP3A4), thus affecting the metabolism and pharmacokinetics of padsevonil when given in combination. Clinical studies have specifically evaluated the pharmacokinetic interactions between padsevonil and erythromycin, confirming that erythromycin increases padsevonil exposure due to inhibition of CYP3A4-mediated metabolism[1][2][3].